{"id":"NCT02109562","sponsor":"Indivior Inc.","briefTitle":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2014-04-10","resultsPosted":"2018-10-26","lastUpdate":"2018-10-26"},"enrollment":354,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"RBP-7000","otherNames":["risperidone in Atrigel"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"RBP-7000 90 mg","type":"EXPERIMENTAL"},{"label":"RBP-7000 120 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of RBP-7000 compared with placebo in the treatment of patients with schizophrenia.\n\nThis will be a double-blind, placebo-controlled, Phase III study with 90 mg and 120 mg doses of RBP-7000 compared with placebo over an 8-week treatment period.","primaryOutcome":{"measure":"Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation","effectByArm":[{"arm":"RBP-7000 90 mg","deltaMin":-15.367,"sd":1.223},{"arm":"RBP-7000 120 mg","deltaMin":-16.456,"sd":1.2073},{"arm":"Placebo","deltaMin":-9.219,"sd":1.2162}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0004"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["34551220","34551219","34551218"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":115},"commonTop":["Injection site pain","Headache","Weight increased","Toothache","Constipation"]}}